BMRA
NASDAQBiomerica Inc.
SectorHealth CareIndustryBiotechnology: In Vitro & In Vivo Diagnostic Substances
News · 26 weeks24-10%
2026-04-192026-10-11
Mix1990d
- SEC Filings10(53%)
- Insider6(32%)
- Other3(16%)
Latest news
25 items- SECSEC Form DEF 14A filed by Biomerica Inc.DEF 14A - BIOMERICA INC (0000073290) (Filer)
- PRBiomerica Reports First Quarter Fiscal 2027 Financial ResultsInFoods® IBS Commercial Progress: Medicare-related test orders increased 120% in September 2026 compared to August, with growing physician participation and repeat ordering activityInFoods® IBS update: 100% of all initial valid Medicare claims processed as of October 15, 2026 have been paid at the full CMS payment rate of $300Engaged B. Riley Securities, Inc. to support the Board's ongoing evaluation of potential strategic opportunities, including partnerships and business combinationsTotal operating expenses decreased approximately 14% year over yearOver-the-counter sales increased approximately 81% compared to the first quarter of fiscal 2026Cash and cash equivalents more than doubled to a
- SECSEC Form 10-Q filed by Biomerica Inc.10-Q - BIOMERICA INC (0000073290) (Filer)
- SECSEC Form 8-K filed by Biomerica Inc.8-K - BIOMERICA INC (0000073290) (Filer)
- SECSEC Form EFFECT filed by Biomerica Inc.EFFECT - BIOMERICA INC (0000073290) (Filer)
- SECSEC Form EFFECT filed by Biomerica Inc.EFFECT - BIOMERICA INC (0000073290) (Filer)
- SECAmendment: SEC Form 10-K/A filed by Biomerica Inc.10-K/A - BIOMERICA INC (0000073290) (Filer)
- SECSEC Form S-3 filed by Biomerica Inc.S-3 - BIOMERICA INC (0000073290) (Filer)
- SECSEC Form S-3 filed by Biomerica Inc.S-3 - BIOMERICA INC (0000073290) (Filer)
- INSIDERSEC Form 3 filed by new insider Qu Xiaoxuan3 - BIOMERICA INC (0000073290) (Issuer)
- PRBiomerica Reports Fiscal 2026 Year-End Financial ResultsFiscal 2026 fourth quarter net sales increased approximately 17% compared to the fourth quarter of fiscal 2025Full-year net loss improved by approximately 24% to approximately $3.8 millionInFoods IBS update: 100% of all initial valid claims processed to date have been paid at the full CMS payment rate of $300Research and development expenses decreased 23% as key programs transition toward commercializationSubsequent to fiscal year-end: completed a $2.23 million financing with no warrants or discounted securities, including participation from B. Riley Principal Capital, B. Riley executives and all members of the board of directorsEngaged B. Riley Securities, Inc. to support the Board's ongoin
- SECSEC Form 10-K filed by Biomerica Inc.10-K - BIOMERICA INC (0000073290) (Filer)
- INSIDERDirector Gary M. Huff bought $50,000 worth of shares (31,250 units at $1.60), increasing direct ownership by 156% to 51,250 units (SEC Form 4)4 - BIOMERICA INC (0000073290) (Issuer)
- INSIDERDirector Moatazedi David bought $16,000 worth of shares (10,000 units at $1.60), increasing direct ownership by 33% to 40,625 units (SEC Form 4)4 - BIOMERICA INC (0000073290) (Issuer)
- INSIDERDirector Chin Eric bought $10,000 worth of shares (6,250 units at $1.60), increasing direct ownership by 19% to 38,750 units (SEC Form 4)4 - BIOMERICA INC (0000073290) (Issuer)
- INSIDERChief Executive Officer Irani Zackary S. bought $50,000 worth of shares (31,250 units at $1.60), increasing direct ownership by 15% to 242,570 units (SEC Form 4)4 - BIOMERICA INC (0000073290) (Issuer)
- INSIDERExecutive Vice Chairman Barbieri Allen bought $32,000 worth of shares (20,000 units at $1.60), increasing direct ownership by 37% to 73,542 units (SEC Form 4)4 - BIOMERICA INC (0000073290) (Issuer)
- PRBiomerica Announces $2.23 Million FinancingFinancing priced at $1.60 with no warrants or discountB. Riley Principal Capital and B. Riley executives, as well as Biomerica's CEO and all members of Biomerica’s Board of Directors participated in the financingProceeds expected to strengthen the Company's balance sheet and fund operations and support the Board's ongoing evaluation of potential strategic opportunities, including partnerships and business combinations IRVINE, Calif., Aug. 27, 2026 (GLOBE NEWSWIRE) -- Biomerica, Inc. (NASDAQ:BMRA) ("Biomerica" or the "Company"), a developer and manufacturer of diagnostic test systems, today announced that it has entered into definitive agreements with institutional and individual investors
- SECBiomerica Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits8-K - BIOMERICA INC (0000073290) (Filer)
- SECBiomerica Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Financial Statements and Exhibits8-K - BIOMERICA INC (0000073290) (Filer)
- PRBiomerica Lands a $1.75 Million CDMO Master Services Agreement for IVD Diagnostic DevelopmentIRVINE, Calif., May 28, 2026 (GLOBE NEWSWIRE) -- Biomerica, Inc. (NASDAQ:BMRA), a developer and manufacturer of diagnostic test systems and CDMO services provider, today announced it has entered into a Master Services Agreement (MSA) with a confidential life sciences company to develop proprietary in vitro diagnostic (IVD) assays. The engagement carries an initial contract development target fee of over $1.75 million, to be earned across multiple Statements of Work (SOWs) under the MSA. Biomerica was chosen following a competitive evaluation in which multiple CDMO organizations were assessed. The MSA establishes an initial three-year term with automatic one-year renewals. All developm
- PRConsumerDirect Expands Executive Team with Appointment of Gary Lu, CPA as Chief Financial OfficerVeteran finance and operations leader brings more than 20 years of experience across public companies and high-growth organizations ConsumerDirect Inc., an industry leader in helping consumers manage their credit, money, and privacy, today announced the appointment of Gary Lu, CPA as Chief Financial Officer. Mr. Lu brings more than two decades of financial, accounting, and operational leadership across public companies, high-growth fintech, and Fortune 500 enterprises. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260519292056/en/Gary Lu, Chief Financial Officer In his role as Chief Financial Officer, Mr. Lu will oversee the
- ANALYSTCitizens initiated coverage on Biomerica with a new price targetCitizens initiated coverage of Biomerica with a rating of Mkt Outperform and set a new price target of $9.00
- PRBiomerica's inFoods® IBS Data Accepted for Presentation at Digestive Disease Week 2026IRVINE, Calif., April 29, 2026 (GLOBE NEWSWIRE) -- Biomerica, Inc. (NASDAQ:BMRA), a global biomedical technology company focused on innovative diagnostic-guided therapies, today announced that an abstract evaluating the real-world clinical effectiveness of its inFoods® IBS diagnostic-guided therapy has been accepted for poster presentation at Digestive Disease Week® (DDW) 2026, to be held May 2–5, 2026, at McCormick Place in Chicago, Illinois. DDW is the world's largest gathering of physicians, researchers, and industry professionals in gastroenterology, hepatology, and related GI disciplines. Acceptance of this poster reflects the growing interest within the gastroenterology community in
- PRBiomerica Announces Medicare Administrative Contractor Confirmation of Individual Claim Review for inFoods® IBS, Opening a Scalable Medicare Commercialization PathwayThe Medicare Administrative Contractor (MAC) responsible for processing inFoods® IBS claims has confirmed to Biomerica's certified laboratory partner that the test will be reviewed on an individual, claim-by-claim basis under Medicare's standard claims approval process.The Company's laboratory partner believes that properly documented claims — with appropriate diagnosis codes and evidence of medical necessity — are eligible for payment under existing $300 CMS payment rate. The inFoods® IBS test holds a dedicated CPT® Proprietary Laboratory Analyses (PLA) code and a CMS-established national payment rate of $300, prerequisites for Medicare claims submissions. Payment rates apply to claims appr
BMRA FAQ
6 questionsWhat does Biomerica Inc. do?
Biomerica, Inc., a biomedical technology company, develops, patents, manufactures, and markets diagnostic and therapeutic products for the detection and/or treatment of medical conditions and diseases worldwide. The company's diagnostic test kits are used to analyze blood, urine, or fecal specimens from patients in the diagnosis of various diseases and other medical complications; or to measure the level of specific bacteria, hormones, antibodies, antigens, or other substances, which exist in the patient's body and stools or blood in extremely small concentrations. It primarily sells its...Where does BMRA stock trade?
Biomerica Inc. (BMRA) is listed on NASDAQ.What sector and industry is BMRA in?
Biomerica Inc. operates in the Health Care sector, Biotechnology: In Vitro & In Vivo Diagnostic Substances industry.What are analysts saying about BMRA?
Biomerica Inc. has had 1 recent analyst action on file. The most recent action was from Citizens: Mkt Outperform with a $900.00 price target on 2026-05-05. Recent price targets cluster around $900.00.What companies are similar to BMRA?
Notable peers in the same industry include IDXX (IDEXX Laboratories Inc.), LNTH (Lantheus Holdings Inc.), ORKA (Oruka Therapeutics Inc.), OCDX (Ortho Clinical Diagnostics Holdings plc), NEOG (Neogen Corporation). Compare BMRA side-by-side with any of them on Quantisnow.How can I track BMRA on Quantisnow?
Quantisnow aggregates Biomerica Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow BMRA to receive live email and push alerts on every new disclosure.